A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers

被引：0
|
作者：
Harding, J. [1 ]
Hofheinz, R. [2 ]
Elez, E. [3 ]
Kuboki, Y. [4 ]
Geng, J. [5 ]
Schmohl, M. [6 ]
Dowling, E. [5 ]
Feng, Y. [5 ]
Rasco, D. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Klinikum Mannheim, Mannheim, Germany
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Natl Canc Ctr East, Kashiwa, Chiba, Japan
[5] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[7] START Ctr Canc Care, San Antonio, TX USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-169
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [41] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
    Savona, Michael R.
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Harb, Wael
    Kantarjian, Hagop
    Lowder, James
    Oganesian, Aram
    Azab, Mohammad
    Garcia-Manero, Guillermo
    LANCET HAEMATOLOGY, 2019, 6 (04): : E194 - E203
  • [42] An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
    Dudek, M. A.
    Zaslona, Z.
    Blaszczyk, R.
    Grzybowski, M. M.
    Rejczak, T.
    Cabaj, A.
    Dera, P.
    Lisiecki, K.
    Iwanowski, P.
    Charitos, T.
    Fung, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S495 - S495
  • [43] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [44] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Mettu, Niharika B.
    Ulahannan, Susanna, V
    Bendell, Johanna C.
    Garrido-Laguna, Ignacio
    Strickler, John H.
    Moore, Kathleen N.
    Stagg, Robert
    Kapoun, Ann M.
    Faoro, Leonardo
    Sharma, Sunil
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
  • [45] A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.
    Spira, Alexander I.
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Kim, Sang-We
    Hong, Min Hee
    Dusek, Rachel
    Gammon, Guy M.
    Wilson, Keith
    Yang, James Chih-Hsin
    Massarelli, Erminia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [47] A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
    Blackman, Samuel C.
    Gainer, Shelby D.
    Suttle, Benjamin B.
    Skordos, Konstantine W.
    Greshock, Joel D.
    Motwani, Monica
    Roadcap, Lori T.
    Hardwicke, Mary Ann A.
    Wooster, Richard F.
    CANCER RESEARCH, 2012, 72
  • [48] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [49] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [50] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345